Immune Responses to Malaria, HIV and SARS-CoV-2 Infection and Immunization - Clinical Core

对疟疾、HIV 和 SARS-CoV-2 感染和免疫的免疫反应 - 临床核心

• 批准号: 10419582
• 负责人: Margaret Juliana McElrath
• 金额: $ 17.68万
• 依托单位: SEATTLE CHILDREN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-07-19 至 2027-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10419582
• 关键词: 2019-nCoV; Clinical; Clinical Trials; Collaborations; Communicable Diseases; Doctor of Philosophy; Fred Hutchinson Cancer Research Center; Future; Goals; HIV; HIV-1; Human; Human Subject Research; Immune; Immune response; Immunization; Immunology; Infection; Investigation; Leadership; Malaria; Observational Study; Prevention; SARS-CoV-2 infection; Specimen; Vaccine Clinical Trial; Vaccines; base; clinical infrastructure; cohort; design; vaccine trial

The Clinical Core will continue to provide the leadership and expertise in clinical infectious diseases and human subjects research to support the HIPC3 and our collaboration’s three scientific projects focused on comprehensive immune analysis of malaria, HIV-1 and SARS-CoV-2 prevention and infection. Based within the Vaccine and Infectious Disease Division at Fred Hutchinson Cancer Research Center, the Clinical Core will establish, conduct and oversee clinical cohort observational studies and human immunology studies nested within clinical vaccine trials in order to obtain longitudinal specimens for deep immune profiling investigations. To accomplish our goals, we propose to provide the clinical infrastructure, leadership, expertise and to conduct human subjects research in infectious diseases on behalf of our HIPC3 Collaboration through observational studies and sub-studies nested within existing and future clinical trials. We also aim to design, develop, implement and maintain well-curated clinical cohorts and vaccine trial sub-studies to acquire specimens for immune profiling studies relevant to malaria, HIV-1 and SARS-CoV-2, either during or after infection, or before and after immunization.

临床核心将继续提供临床传染病和人类的领导和专业知识 受试者研究支持HIPC3及其合作的三个科学项目，重点介绍 疟疾，HIV-1和SARS-COV-2预防和感染的全面免疫学分析。基于 弗雷德·哈钦森癌症研究中心的疫苗和传染病分裂，临床核心将 建立，进行和监督临床队列观测研究和人类免疫学研究 在临床疫苗试验中，以获取纵向标本进行深度免疫分析研究。 为了实现我们的目标，我们建议提供临床基础设施，领导力，专业知识并进行 人类受试者通过观察性代表我们的HIPC3合作研究中的传染病研究 研究和子研究嵌套在现有和未来的临床试验中。我们还旨在设计，开发， 实施并维护经过良好策划的临床队列和疫苗试验子研究，以获取标本 在感染或之前或之前，与疟疾，HIV-1和SARS-COV-2相关的免疫分析研究 并在免疫后。